Liu Yalan, Li Yuncheng, Hu Qinxue
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.
Hubei Jiangxia Laboratory, Wuhan 430200, China.
Vaccines (Basel). 2023 Jun 24;11(7):1142. doi: 10.3390/vaccines11071142.
Although conventional vaccine approaches have proven to be successful in preventing infectious diseases in past decades, for vaccine development against emerging/re-emerging viruses, one of the main challenges is rapid response in terms of design and manufacture. mRNA vaccines can be designed and produced within days, representing a powerful approach for developing vaccines. Furthermore, mRNA vaccines can be scaled up and may not have the risk of integration. mRNA vaccines are roughly divided into non-replicating mRNA vaccines and self-amplifying RNA (saRNA) vaccines. In this review, we provide an overview of saRNA vaccines, and discuss future directions and challenges in advancing this promising vaccine platform to combat emerging/re-emerging viruses.
尽管传统疫苗方法在过去几十年已被证明在预防传染病方面取得了成功，但对于针对新出现/再次出现的病毒开发疫苗而言，主要挑战之一是在设计和生产方面的快速响应。信使核糖核酸（mRNA）疫苗可在数天内设计和生产出来，是一种强大的疫苗开发方法。此外，mRNA疫苗可以扩大规模，且可能不存在整合风险。mRNA疫苗大致分为非复制型mRNA疫苗和自我扩增RNA（saRNA）疫苗。在本综述中，我们概述了saRNA疫苗，并讨论了推进这一有前景的疫苗平台以对抗新出现/再次出现的病毒的未来方向和挑战。
